GIP receptor activation Glucose-dependent insulinotropic polypeptide (GIP) is the second receptor target, similar to tirzepatide (Mounjaro, Zepbound): Effects: Enhances insulin release from the pancreas Works synergistically with GLP-1 for appetite control May influence fat storage and energy balance Improves glucose regulation Tirzepatide's success as a dual GLP-1/GIP agonist demonstrated that adding GIP to GLP-1 enhances weight loss beyond GLP-1 alone
Available from: Xiao P, Wang H, Liu H, Yuan H, Guo C, Feng Y, et al
When food stays in the stomach or intestines too long, bacteria may break it down and release gas
Works for injectable GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro, semaglutide, tirzepatide, compounded forms) and oral GLP-1s (Rybelsus, oral Wegovy, Foundayo, orforglipron)